Pharmacokinetics of Intracellular TFV-DP and FTC-TP in HIV-infected Adolescents

Tuberculosis Clinical Trial

Official title:

Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03800394
• Other study ID #: IRB201801820 - PKAdol
• Secondary ID: 2R01HD071779
• Status: Recruiting
• Start date: January 28, 2019
• Est. completion date: August 31, 2024

Study information

• Verified date: June 2023
• Source: University of Florida
• Contact: Awewura Kwara, MD
• Phone: 352-273-9501
• Email: awewura.kwara[@]medicine.ufl.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Tenofovir (TFV) disoproxil fumarate (TDF) plus emtricitabine (FTC) or lamivudine (3TC) is the preferred nucleoside backbone of first-line antiretroviral therapy (ART) for adolescents in sub-Saharan Africa. In addition, TDF/FTC is recommended for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection in adolescents at substantial risk of acquisition of HIV infection, as well as for hepatitis B virus (HBV) treatment in those with HBV/HIV coinfection. The efficacy TDF and FTC are dependent on intracellular concentrations of the active phosphate anabolites, called TFV diphosphate (TFV-DP) and FTC triphosphate (FTC-TP). However, the intracellular pharmacokinetics of TFV-DP and FTC-TP to examine the adequacy of current dosages in African adolescents has not been previously studied. Thus, examining the pharmacokinetics (PK) of these widely used antiretrovirals in African adolescents is important as ART outcomes remain poor and the recommended dosages of these drugs for children and adolescent were extrapolated from drug approval clinical trials in adult in the United States and Europe.

Description:

This study will evaluate the intracellular PK of TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents with and without TB coinfection. As the clinical effects of TDF and FTC are related to the intracellular concentrations of the phosphate anabolites, called TFV-DP and FTC-TP, there is a need to understand the cellular pharmacology of TDF interactions in African HIV-infected adolescents with and without TB, as the study team cannot extrapolate from US patients not on antituberculosis (anti-TB) drugs. This study will enroll HIV-infected adolescents aged 10 to 18 years old with and without TB coinfection who are already established on ART. The study team hypothesize that younger age, adenosine triphosphate (ATP)-binding cassette subfamily C (ABCC) single nucleotide polymorphisms (SNPs) and anti-TB therapy may influence the intracellular TFV-DP and FTC-TP concentrations in adolescents.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 382
• Est. completion date: August 31, 2024
• Est. primary completion date: August 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 10 Years to 19 Years

Eligibility

Inclusion Criteria:

• HIV-infected adolescents aged 10 to 19 years old who are stable on antiretroviral regimen containing TDF/FTC (300/200 mg daily) for at least 8 weeks.

Exclusion Criteria:

• Unable to obtain informed signed consent from parent(s) or legal guardian.
• Pregnant or breast feeding.
• Require therapy for other opportunistic infections other than tuberculosis (TB).

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• Coinfection
• HIV Infections
• Human Immunodeficiency Virus (HIV)
• Tuberculosis

Intervention

Other:
• Observational PK study
Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations

Locations

Country	Name	City	State
Ghana	Kwame Nkrumah University of Science and Technology	Kumasi

Sponsors (2)

Lead Sponsor	Collaborator
University of Florida	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

Ghana, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Average concentration (Cav) of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.	Mean and median Cav of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.	After at least 8 weeks of HIV therapy.
Primary	Area under the time-concentration curve 0-24 hours (AUC0-24h) of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.	Mean and median AUC0-24h of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.	After at least 8 weeks of HIV therapy.
Primary	Cav of TFV-DP and FTC-TP PK in HIV-infected adolescents with and without TB coinfection.	Geometric mean intracellular TFV-DP and FTC-TP Cav in adolescents with TB/HIV coinfection compared to those only HIV infection.	After at least 8 weeks of HIV therapy.
Primary	AUC0-24h of TFV-DP and FTC-TP PK in HIV-infected adolescents with and without TB coinfection.	Geometric mean of intracellular TFV-DP and FTC-TP AUC0-24h in adolescents with TB/HIV coinfection compared to those with only HIV infection.	After at least 8 weeks of HIV therapy.
Secondary	Effect of age on TFV-DP and FTC-TP Cav.	Geometric mean of intracellular TFV-DP and FTC-TP Cav in adolescents aged 10 - 14 years old compared to that in adolescents aged 15 - 19 years old.	After at least 8 weeks of HIV therapy.
Secondary	Effect of age on TFV-DP and FTC-TP AUC0-24h .	Geometric mean of intracellular TFV-DP and FTC-TP AUC0-24h in adolescents aged 10 - 14 years old compared to that in adolescents aged 15 - 19 years old.	After at least 8 weeks of HIV therapy.
Secondary	Intracellular TFV-DP and FTC-TP Cav in adolescents compared to that in historical adult controls.	Geometric mean of intracellular TFV-DP and FTC-TP Cav in Ghanaian HIV-infected adolescent compared to published values in adults treated with similar dosage.	After at least 8 weeks of HIV therapy.
Secondary	Intracellular TFV-DP and FTC-TP AUC0-24h in adolescents compared to that in historical adult controls.	Geometric mean of intracellular TFV-DP and FTC-TP AUC0-24h in Ghanaian HIV-infected adolescent compared to published values in adults treated with similar dosage.	After at least 8 weeks of HIV therapy.
Secondary	Relationship between Adenosine triphosphate (ATP)-binding cassette subfamily C, member 2 (ABCC2), member 4 (ABCC4) and member 10 (ABCC10) SNPs and TFV-DP and FTC-TP AUC0-24h.	Relationship between ABCC2, ABCC4 and ABCC10 SNPs and intracellular TFV-DP and FTC-TP AUC0-24h.	After at least 8 weeks of HIV therapy.
Secondary	Prevalence and covariates of intracellular TFV-DP Cav < 95 fmol/106 cells in adolescents.	Proportion of Ghanaian adolescents and factors associated with intracellular TFV-DP average concentration < 95 fmol/106 cells.	After at least 8 weeks of HIV therapy.